CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Blood drawWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug632 Placebos Wiki 0.19
drug360 Hydroxychloroquine Wiki 0.09

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.35
D003141 Communicable Diseases NIH 0.08
D018352 Coronavirus Infections NIH 0.08
D014777 Virus Diseases NIH 0.08
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Acquiring Convalescent Specimens to Isolate and Identify Potent Monoclonal Antibodies Against COVID-19

Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify antibodies that have been generated by the patient to fight the COVID-19 infection. By identifying the most effective antibodies, scientists can make specific antibodies to use to prevent future coronavirus outbreaks or to treat patients with severe disease.

NCT04342195 COVID-19 Coronavirus Infection Corona Virus Infection Procedure: Blood draw
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Virus Diseases

Primary Outcomes

Description: The blood specimen will be proceeded into peripheral blood mononuclear cells and plasma to be stored for testing. In brief, CD27+ memory B cells that can bind to a SARS-CoV-2 S protein bait will be sorted by flow cytometry and RNA will be extracted to obtain heavy and light chain sequences. Antibody sequences will be annotated using bioinformatics approaches, and candidate sequences will be cloned. Purified antibodies will be characterized and neutralization breadth and potency against SARS-CoV-2 and other related coronaviruses will be assessed using neutralization assays.

Measure: Number of antibodies against coronaviruses isolated and identified from patient samples

Time: Up to 12 months after collection visit

2 Precision Immunology Approach to Better Understand the Divergent Host Responses Towards Infection With SARS-CoV-2

To better understand the immune response to SARS-CoV-2 infection, we devised a precision immunology approach to systematically study the immune function of different patient cohorts

NCT04360733 SARS-CoV 2 COVID Other: Blood draw

Primary Outcomes

Description: Immune response of whole blood stimulation assay with various immune activators will be measured by FACS and multiplex Assay

Measure: Immune response

Time: 4 weeks

No related HPO nodes (Using clinical trials)